Research programme: small molecules - IM Therapeutics

Alternative Names: IMT 002; Methyldopa D-enantiomer

Latest Information Update: 08 Dec 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator University of Colorado at Denver
Class Antihyperglycaemics; Small molecules
Mechanism of Action Alpha 2 adrenergic receptor agonists; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Type 1 diabetes mellitus
New Molecular Entity No

Highest Development Phases

Preclinical Type 1 diabetes mellitus
Research Autoimmune disorders

Most Recent Events

21 Dec 2017 IM Therapeutics plans a clinical trial of IMT 002 for type 1 diabetes mellitus in 2018
06 Dec 2017 IM Therapeutics licenses worldwide rights to methyldopa and D enantiomer of methyldopa from the University of Colorado
06 Dec 2017 IM Therapeutics has patent protection for Methyldopa and D enantiomer of methyldopa (IMT 002) in USA

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.